These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11912295)

  • 1. The acute phase response in chronic haemodialysis patients: a marker of cardiovascular disease?
    Nubé MJ
    Nephrol Dial Transplant; 2002; 17 Suppl 3():19-23. PubMed ID: 11912295
    [No Abstract]   [Full Text] [Related]  

  • 2. The microinflammatory state of uremia.
    Schömig M; Eisenhardt A; Ritz E
    Blood Purif; 2000; 18(4):327-32. PubMed ID: 10965076
    [No Abstract]   [Full Text] [Related]  

  • 3. Inflammation and cardiovascular risk in dialysis patients.
    Wanner C; Zimmermann J; Schwedler S; Metzger T
    Kidney Int Suppl; 2002 May; (80):99-102. PubMed ID: 11982822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Another Marker of Cardiac Dysfunction in Dialysis Patients?
    Zoccali C
    Nephron Clin Pract; 2003; 93(2):C49-50. PubMed ID: 12616030
    [No Abstract]   [Full Text] [Related]  

  • 5. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients.
    Wanner C; Zimmermann J; Quaschning T; Galle J
    Kidney Int Suppl; 1997 Nov; 62():S53-5. PubMed ID: 9350681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients.
    Walter R; Mischak H; Haller H
    Nephrol Dial Transplant; 2002; 17 Suppl 3():24-9. PubMed ID: 11912296
    [No Abstract]   [Full Text] [Related]  

  • 7. Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
    Almirall J; Valenzuela MP; Lopez T
    Nephrol Dial Transplant; 2007 Jan; 22(1):281; author reply 281-2. PubMed ID: 17085461
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.
    Furuhashi M; Ura N; Hasegawa K; Yoshida H; Tsuchihashi K; Nakata T; Shimamoto K
    Nephron Clin Pract; 2003; 93(2):C69-74. PubMed ID: 12616033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response.
    Borawski J; Naumnik B; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2001 Jul; 16(7):1442-7. PubMed ID: 11427638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological markers of inflammation and carpal tunnel syndrome in dialysis patients.
    Curatola G; Malara E; Sisca S; Enia G; Postorino M; Cutrupi S; Zoccali C; Maggiore Q
    Nephron; 1990; 56(4):453-4. PubMed ID: 2127823
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis.
    Friedman JA; Dwyer JT
    Nutr Rev; 1995 Jul; 53(7):197-201. PubMed ID: 7494622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carotid intima-media thickness as a marker of atherosclerosis in hemodialysis patients.
    Moshkani Farahani M
    Iran J Kidney Dis; 2012 May; 6(3):161-2. PubMed ID: 22555475
    [No Abstract]   [Full Text] [Related]  

  • 13. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure.
    Stenvinkel P
    Blood Purif; 2001; 19(2):143-51. PubMed ID: 11150801
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of graft and patient outcomes following kidney transplantation in extended hour and conventional haemodialysis patients.
    See EJ; Hawley CM; Cho Y; Toussaint ND; Agar JW; Pascoe EM; Lim WH; Francis RS; Collins MG; Johnson DW
    Nephrology (Carlton); 2019 Jan; 24(1):111-120. PubMed ID: 29316017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Countermeasure for patients with cardiovascular diseases due to hemodialysis].
    Tabei K; Asano Y
    Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1678-84. PubMed ID: 8537724
    [No Abstract]   [Full Text] [Related]  

  • 16. Anaemia and early phase cardiovascular events on haemodialysis.
    Hayashi T; Joki N; Tanaka Y; Hase H
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():1-6. PubMed ID: 26456311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess cardiovascular mortality in chronic dialysis patients.
    Abbott KC
    Am J Kidney Dis; 2002 Dec; 40(6):1349-50. PubMed ID: 12460060
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dialysis-induced heart and circulatory changes in normo- and hypervolemic chronic dialysis patients].
    Twittenhoff WD; Stegaru B; Burkhard E; Bähr R; Brittinger WD
    Verh Dtsch Ges Inn Med; 1975; 81():989-92. PubMed ID: 820120
    [No Abstract]   [Full Text] [Related]  

  • 19. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress.
    Kosch M; Levers A; Fobker M; Barenbrock M; Schaefer RM; Rahn KH; Hausberg M
    Nephrol Dial Transplant; 2003 Jul; 18(7):1370-5. PubMed ID: 12808175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular complications in chronic kidney failure patients undergoing systematic hemodialysis].
    Dzhavad-Zade MD; Agaev MM
    Urol Nefrol (Mosk); 1985; (6):54-8. PubMed ID: 4090119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.